Sacubitril-valsartan improves conduit vessel function and functional capacity and reduces inflammation in heart failure with reduced ejection fraction

Author:

Bunsawat Kanokwan1ORCID,Ratchford Stephen M.123ORCID,Alpenglow Jeremy K.4,Park Soung Hun4,Jarrett Catherine L.12ORCID,Stehlik Josef5,Smith Adam S.6,Richardson Russell S.124,Wray D. Walter124

Affiliation:

1. Division of Geriatrics, Department of Internal Medicine, University of Utah, Salt Lake City, Utah

2. Geriatric Research, Education, and Clinical Center, George E. Wahlen Department of Veterans Affairs Medical Center, Salt Lake City, Utah

3. Department of Health & Exercise Science, Appalachian State University, Boone, North Carolina

4. Department of Nutrition and Integrative Physiology, University of Utah, Salt Lake City, Utah

5. Division of Cardiovascular Medicine, Department of Internal Medicine, University of Utah, Salt Lake City, Utah

6. Department of Pharmacy Services, University of Utah, Salt Lake City, Utah

Abstract

We observed an approximately twofold improvement in conduit vessel function (brachial artery FMD), increased functional capacity (6MWT distance), and a reduction in inflammation (TNF-α and IL-18) following 3 mo of sacubitril-valsartan therapy. These findings provide important new information concerning the physiological mechanisms by which this new drug class provokes favorable changes in HFrEF pathophysiology.

Funder

American Heart Association

HHS | National Institutes of Health

U.S. Department of Veterans Affairs

Publisher

American Physiological Society

Subject

Physiology (medical),Physiology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3